Top

Published in:

01-07-2019 | Substantive Review

A Review of Approaches Used to Increase Awareness of Pre-exposure Prophylaxis (PrEP) in the United States

Authors: Amber I. Sophus, Jason W. Mitchell

Published in: AIDS and Behavior | Issue 7/2019

Abstract

PrEP is an important and useful HIV prevention strategy, yet awareness remains low among at-risk populations in the United States and elsewhere in the world. As previous studies have shown PrEP awareness to be important to PrEP uptake, understanding approaches to increase PrEP awareness is imperative. The current systematic review provides an overview of published articles and on-going research on PrEP awareness. Using PRISMA guidelines, two published articles and seven on-going research studies were identified that use different approaches to increase PrEP awareness. Findings highlight the need for research to target other at-risk populations and geographic areas. Future research should consider the use of technology and network approaches to assess whether they lead to increased awareness, accurate knowledge, and uptake of PrEP, along with examining which messaging works best for specific targeted, at-risk population(s).

Available only for authorised users

Centers for Disease Control and Prevention. HIV surveillance Report, vol. 28. Atlanta: CDC; 2016.

Centers for Disease Control and Prevention. HIV Transmission. https://www.cdc.gov/hiv/basics/transmission.html. Accessed 13 Aug 2018.

Centers for Disease Control and Prevention. Pre-Exposure Prophylaxis (PrEP) 2017. http://www.cdc.gov/hiv/risk/prep/index.html. Accessed 31 Aug 2017.

Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral

Celum C, Baeten JM. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis. 2012;25(1):51–7.CrossRefPubMedPubMedCentral

Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMed

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral

Grohskopf LA, Chillag KL, Gvetadze R, Liu AY, Thompson M, Mayer KH, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013;64(1):79–86.CrossRefPubMed

McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.CrossRefPubMedPubMedCentral

10.

Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.CrossRefPubMed

11.

Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMed

12.

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.CrossRefPubMedPubMedCentral

13.

U.S Food and Drug Administration. Truvada for PrEP fact sheet: ensuring safe and proper use. 2012.

14.

Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of hiv infeciton in the United States—2014: a clinical practice guideline. Washington, DC: US Public Health Service; 2014.

15.

Centers for Disease Control and Prevention. HIV prevention pill not reaching most Americans who could benefit—especially people of color 2018. https://www.cdc.gov/nchhstp/newsroom/2018/croi-2018-PrEP-press-release.html. Accessed 6 March 2018.

16.

White House. National HIV/AIDS Strategy for the United States: Updated to 2020. 2017.

17.

Garnett M, Hirsch-Moverman Y, Franks J, Hayes-Larson E, El-Sadr WM, Mannheimer S. Limited awareness of pre-exposure prophylaxis among black men who have sex with men and transgender women in New York city. AIDS Care. 2018;30(1):9–17.CrossRefPubMed

18.

Rowniak S, Ong-Flaherty C, Selix N, Kowell N. Attitudes, beliefs, and barriers to PrEP among trans men. AIDS Educ Prev. 2017;29(4):302–14.CrossRefPubMed

19.

Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDS. 2015;29(2):102–10.CrossRefPubMedPubMedCentral

20.

Collier KL, Colarossi LG, Sanders K. Raising awareness of pre-exposure prophylaxis (PrEP) among women in New York City: community and provider perspectives. J Health Commun. 2017;22(3):183–9.CrossRefPubMed

21.

Walters SM, Reilly KH, Neaigus A, Braunstein S. Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. Harm Reduct J. 2017;14(1):40.CrossRefPubMedPubMedCentral

22.

Parsons JT, Rendina HJ, Lassiter JM, Whitfield TH, Starks TJ, Grov C. Uptake of HIV pre-exposure prophylaxis (PrEP) in a National cohort of gay and bisexual men in the United States. J Acquir Immune Defic Syndr. 2017;74(3):285–92.CrossRefPubMedPubMedCentral

23.

Kelley CF, Kahle E, Siegler A, Sanchez T, Del Rio C, Sullivan PS, et al. Applying a PrEP continuum of care for men who have sex with men in Atlanta, Georgia. Clin Infect Dis. 2015;61(10):1590–7.CrossRefPubMedPubMedCentral

24.

Trevethan R. Deconstructing and assessing knowledge and awareness in public health research. Front Public Health. 2017;5:194.CrossRefPubMedPubMedCentral

25.

Coulaud et al, editor “Yes, I would like to use pre-exposure prophylaxis”: results from a cohort of HIV-negative men who have sex with men in West Africa. AIDSImpact; 2017 November 13–15; Cape Town, South Africa.

26.

Barash EA, Golden M. Awareness and use of HIV pre-exposure prophylaxis among attendees of a seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDS. 2010;24(11):689–91.CrossRefPubMed

27.

Young I, Li J, McDaid L. Awareness and willingness to use HIV pre-exposure prophylaxis amongst gay and bisexual men in Scotland: implications for biomedical HIV prevention. PLoS ONE. 2013;8(5):e64038.CrossRefPubMedPubMedCentral

28.

Yi S, Tuot S, Mwai GW, Ngin C, Chhim K, Pal K, et al. Awareness and willingness to use HIV pre-exposure prophylaxis among men who have sex with men in low- and middle-income countries: a systematic review and meta-analysis. J Int AIDS Soc. 2017;20(1):21580.CrossRefPubMedPubMedCentral

29.

Koechlin FM, Fonner VA, Dalglish SL, O’Reilly KR, Baggaley R, Grant RM, et al. Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature. AIDS Behav. 2017;21(5):1325–35.CrossRefPubMed

30.

Frankis JS, Young I, Lorimer K, Davis M, Flowers P. Towards preparedness for PrEP: PrEP awareness and acceptability among MSM at high risk of HIV transmission who use sociosexual media in four Celtic nations: Scotland, Wales, Northern Ireland and The Republic of Ireland: an online survey. Sex Transm Infect. 2016;92(4):279–85.CrossRefPubMed

31.

Garcia M, Harris AL. PrEP awareness and decision-making for Latino MSM in San Antonio, Texas. PLoS ONE. 2017;12(9):e0184014.CrossRefPubMedPubMedCentral

32.

Hoots BE, Finlayson T, Nerlander L, Paz-Bailey G, National HIVBSSG. Willingness to take, use of, and indications for pre-exposure prophylaxis among men who have sex with men-20 US cities, 2014. Clin Infect Dis. 2016;63(5):672–7.CrossRefPubMedPubMedCentral

33.

Zhang Y, Peng B, She Y, Liang H, Peng HB, Qian HZ, et al. Attitudes toward HIV pre-exposure prophylaxis among men who have sex with men in western China. AIDS Patient Care STDS. 2013;27(3):137–41.CrossRefPubMedPubMedCentral

34.

Restar AJ, Tocco JU, Mantell JE, Lafort Y, Gichangi P, Masvawure TB, et al. Perspectives on HIV pre- and post-exposure prophylaxes (PrEP and PEP) among female and male sex workers in Mombasa, Kenya: implications for integrating biomedical prevention into sexual health services. AIDS Educ Prev. 2017;29(2):141–53.CrossRefPubMedPubMedCentral

35.

Rendina HJ, Whitfield TH, Grov C, Starks TJ, Parsons JT. Distinguishing hypothetical willingness from behavioral intentions to initiate HIV pre-exposure prophylaxis (PrEP): findings from a large cohort of gay and bisexual men in the U.S. Soc Sci Med. 2017;172:115–23.CrossRefPubMed

36.

Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1601–3.CrossRefPubMedPubMedCentral

37.

Montgomery MC, Oldenburg CE, Nunn AS, Mena L, Anderson P, Liegler T, et al. Adherence to pre-exposure prophylaxis for HIV prevention in a clinical setting. PLoS ONE. 2016;11(6):e0157742.CrossRefPubMedPubMedCentral

38.

Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75–84.CrossRefPubMedPubMedCentral

39.

Bien CH, Patel VV, Blackstock OJ, Felsen UR. Reaching key populations: PrEP uptake in an urban health care system in the Bronx, New York. AIDS Behav. 2017;21(5):1309–14.CrossRefPubMed

40.

Maughan-Brown B, Venkataramani AS. Accuracy and determinants of perceived HIV risk among young women in South Africa. BMC Public Health. 2018;18(1):42.CrossRef

41.

Hood JE, Buskin SE, Dombrowski JC, Kern DA, Barash EA, Katz DA, et al. Dramatic increase in preexposure prophylaxis use among MSM in Washington state. AIDS (London, England). 2016;30(3):515–9.

42.

Blackstock OJ, Patel VV, Felsen U, Park C, Jain S. Pre-exposure prophylaxis prescribing and retention in care among heterosexual women at a community-based comprehensive sexual health clinic. AIDS Care. 2017;29(7):866–9.CrossRefPubMedPubMedCentral

43.

Niderost S, Gredig D, Hassler B, Uggowitzer F, Weber P. The intention to use HIV-pre-exposure prophylaxis (PrEP) among men who have sex with men in Switzerland: testing an extended explanatory model drawing on the unified theory of acceptance and use of technology (UTAUT). Z Gesundh Wiss. 2018;26(3):247–59.CrossRefPubMed

44.

Mitchell JW, Stephenson R. HIV-negative partnered men’s willingness to use pre-exposure prophylaxis and associated factors among an internet sample of US HIV-negative and HIV-discordant male couples. LGBT Health. 2015;2(1):35–40.CrossRefPubMedPubMedCentral

45.

Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50(1):77–83.CrossRefPubMedPubMedCentral

46.

Zalazar V, Aristegui I, Kerr T, Marshall BDL, Romero M, Sued O, et al. High willingness to use HIV pre-exposure prophylaxis among transgender women in Argentina. Transgend Health. 2016;1(1):266–73.CrossRefPubMedPubMedCentral

47.

Mayer KH, Chan PA, Patel RR, Flash CA, Krakower DS. Evolving models and ongoing challenges for HIV preexposure prophylaxis implementation in the United States. J Acquir Immune Defic Syndr. 2018;77(2):119–27.PubMedPubMedCentral

48.

Kirby T, Thornber-Dunwell M. Uptake of PrEP for HIV slow among MSM. Lancet. 2014;383(9915):399–400.CrossRefPubMed

49.

Wang Z, Lau JTF, Fang Y, Ip M, Gross DL. Prevalence of actual uptake and willingness to use pre-exposure prophylaxis to prevent HIV acquisition among men who have sex with men in Hong Kong, China. PLoS ONE. 2018;13(2):e0191671.CrossRefPubMedPubMedCentral

50.

Lee YC, Chang SY, Lin KY, et al. Awareness and willingness towards pre-exposure prophylaxis against HIV infection among individuals seeking voluntary counselling and testing for HIV in Taiwan: a cross-sectional questionnaire survey. BMJ Open. 2017;7(10):e015142.CrossRefPubMedPubMedCentral

51.

Wade Taylor S, Mayer KH, Elsesser SM, Mimiaga MJ, O’Cleirigh C, Safren SA. Optimizing content for pre-exposure prophylaxis (PrEP) counseling for men who have sex with men: perspectives of PrEP users and high-risk PrEP naive men. AIDS Behav. 2014;18(5):871–9.CrossRefPubMedPubMedCentral

52.

Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS. 2013;27(4):248–54.CrossRefPubMedPubMedCentral

53.

Coleman R, Prins M. Options for affordable pre-exposure prophylaxis (PrEP) in national HIV prevention programmes in Europe. Euro Surveill. 2017. https://doi.org/10.2807/1560-7917.CrossRefPubMedPubMedCentral

54.

Morgan E, Ryan DT, Newcomb ME, Mustanski B. High rate of discontinuation may diminish PrEP coverage among young men who have sex with men. AIDS Behav. 2018. https://doi.org/10.1007/s10461-018-2125-2.CrossRefPubMedPubMedCentral

55.

AVERT. Norway provides PrEP for free to all those at risk of HIV 2016. https://www.avert.org/news/norway-provides-prep-free-all-those-risk-hiv. Accessed 14 Nov 2016.

56.

Scotland HIV. PrEP FAQs Edinburgh, Scottlan. http://www.hivscotland.com/our-work/prep-in-scotland/prep-faqs/.

57.

GILEAD. http://www.gilead.com/.

58.

University of Utah Health. HIV PrEP Clinic. https://healthcare.utah.edu/locations/redwood/hiv-prep-clinic.php.

59.

Healthy San Francisco. Innovative Health Access Program. https://healthysanfrancisco.org/.

60.

Kuo I, Olsen H, Patrick R, Phillips G 2nd, Magnus M, Opoku J, et al. Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington, DC. Drug Alcohol Depend. 2016;164:8–13.CrossRefPubMed

61.

Shrestha R, Karki P, Altice FL, Huedo-Medina TB, Meyer JP, Madden L, et al. Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. Drug Alcohol Depend. 2017;173:107–16.CrossRefPubMedPubMedCentral

62.

Wilson EC, Jin H, Liu A, Raymond HF. Knowledge, indications and willingness to take pre-exposure prophylaxis among transwomen in San Francisco, 2013. PLoS ONE. 2015;10(6):e0128971.CrossRefPubMedPubMedCentral

63.

Eysenbach G. What is e-health? J Med Internet Res. 2001;3(2):E20.CrossRefPubMedPubMedCentral

64.

Steinhubl SR, Muse ED, Topol EJ. The emerging field of mobile health. Sci Transl Med. 2015;7(283):283rv3.CrossRefPubMedPubMedCentral

65.

Blackstock OJ, Patel VV, Cunningham CO. Use of technology for HIV prevention among adolescent and adult women in the United States. Curr Hiv/Aids Rep. 2015;12(4):489–99.CrossRefPubMedPubMedCentral

66.

French RS, Bonell C, Wellings K, Weatherburn P. An exploratory review of HIV prevention mass media campaigns targeting men who have sex with men. BMC Public Health. 2014;14:616.CrossRefPubMedPubMedCentral

67.

Gilead. Pre-exposure prophylaxis (PrEP) for HIV prevention. https://www.gilead.com/-/media/files/pdfs/preexposure%20prophylaxis.pdf?la=en. Accessed Oct 2017.

68.

EU Clinical Trials Register. https://www.clinicaltrialsregister.eu/.

69.

Australian New Zealand Clinical Trials Registry (ANZCTR). http://www.anzctr.org.au/.

70.

AIDS Vaccine Advocacy Coalition (AVAC). https://www.avac.org/.

71.

PrEPWatch. https://www.prepwatch.org/.

72.

Federal RePORTER [Internet]. https://federalreporter.nih.gov/.

73.

ClinicalTrials.gov. Bethesda (MD). https://clinicaltrials.gov/.

74.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.CrossRefPubMed

75.

Raifman J, Nunn A, Oldenburg CE, Montgomery MC, Almonte A, Agwu AL, et al. An evaluation of a clinical pre-exposure prophylaxis education intervention among men who have sex with men. Health Serv Res. 2018;53(4):2249–67.CrossRefPubMed

76.

Sullivan PS, Driggers R, Stekler JD, Siegler A, Goldenberg T, McDougal SJ, et al. Usability and acceptability of a mobile comprehensive HIV prevention app for men who have sex with men: a pilot study. JMIR Mhealth Uhealth. 2017;5(3):e26.CrossRefPubMedPubMedCentral

77.

Bandura A. Social cognitive theory of self-regulation. Organ Behav Hum Decis Process. 1991;50(2):248–87.CrossRef

78.

Centers for Disease Control and Prevention. HIV in the United States by Geography 2018. https://www.cdc.gov/hiv/statistics/overview/geographicdistribution.html.

79.

Centers for Disease Control and Prevention. HIV in Southern United States 2016. https://www.cdc.gov/hiv/pdf/policies/cdc-hiv-in-the-south-issue-brief.pdf. Accessed May 2016.

80.

Patel V. Social media based peer let intervention to facilitate PrEP in YMSM of Color Federal REPORTER [Project No. 5K23MH102118-05]. https://projectreporter.nih.gov/project_info_details.cfm?aid=9095438.

81.

Blackstock OJ, Norton B. PrEP-UP: Peer outreach and navigation intervention to increase PrEP uptake among women at high risk for HIV ClinicalTrials.gov [Identification No. NCT03226873]. https://clinicaltrials.gov/ct2/show/NCT03226873?term=HIV+prevention%2C+PrEP%2C+pre-exposure+prophylaxis%2C+preexposure+prophylaxis&cond=HIV&rank=21.

82.

Schneider J, Advanced HIV, Prevention (PrEP Chicago) ClinicalTrials.gov [Identification No. NCT02896699]. https://clinicaltrials.gov/ct2/show/NCT02896699.

83.

Liu A, Hyman S. LYNX: a novel mobile app to support linkage to HIV/STI testing PrEP for young men who have sex with men ClinicalTrials.gov [Identification No. NCT03177512]. https://clinicaltrials.gov/ct2/show/NCT03177512?term=HIV+prevention%2C+PrEP%2C+pre-exposure+prophylaxis%2C+preexposure+prophylaxis&cond=HIV&rank=60.

84.

Bauermeister J, Stephenson R. Get connected: linking YMSM to adequate care through a multilevel, tailored WebApp intervention: ClinicalTrials.gov; [Identification No. NCT03132415]. https://clinicaltrials.gov/ct2/show/NCT03132415?term=NCT03132415&rank=1.

85.

Kelly J, Amirkhanian Y. Increasing PrEP use in high-risk social networks of African American MSM in underserved low-uptake cities NIH RePORTER [Project No. 1R01NR017574-01]. https://projectreporter.nih.gov/project_info_details.cfm?aid=9568815&icde=0.

86.

Teitelman A. Developing a women-focused PrEP intervention for HIV prevention federal RePORTER [Project No. 1R34MH108437-01A1]. https://federalreporter.nih.gov/Projects/Details/?projectId=826157&ItemNum=23&totalItems=129&searchId=edac8498e41f4c9b86503ac4c97b766a&searchMode=Smart&page=1&pageSize=100&sortField=&sortOrder=&filters=&navigation=True.

87.

Fish J, Papaloukas P, Jaspal R, Williamson I. Equality in sexual health promotion: a systematic review of effective interventions for black and minority ethnic men who have sex with men. BMC Public Health. 2016;16(1):810.CrossRefPubMedPubMedCentral

88.

Hergenrather KC, Emmanuel D, Durant S, Rhodes SD. Enhancing HIV prevention among young men who have sex with men: a systematic review of HIV behavioral interventions for young gay and bisexual men. AIDS Educ Prev. 2016;28(3):252–71.CrossRefPubMed

89.

Knight R, Karamouzian M, Salway T, Gilbert M, Shoveller J. Online interventions to address HIV and other sexually transmitted and blood-borne infections among young gay, bisexual and other men who have sex with men: a systematic review. J Int AIDS Soc. 2017;20(3):e25017.CrossRefPubMedCentral

90.

Lorimer K, Kidd L, Lawrence M, McPherson K, Cayless S, Cornish F. Systematic review of reviews of behavioural HIV prevention interventions among men who have sex with men. AIDS Care. 2013;25(2):133–50.CrossRefPubMed

91.

Ruiz-Perez I, Murphy M, Pastor-Moreno G, Rojas-Garcia A, Rodriguez-Barranco M. The effectiveness of HIV prevention interventions in socioeconomically disadvantaged ethnic minority women: a systematic review and meta-analysis. Am J Public Health. 2017;107(12):e13–21.CrossRefPubMed

92.

Baral SD, Poteat T, Stromdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):214–22.CrossRefPubMed

93.

Garofalo R, Kuhns LM, Reisner SL, Mimiaga MJ. Behavioral interventions to prevent HIV transmission and acquisition for transgender women: a critical review. J Acquir Immune Defic Syndr. 2016;72(Suppl 3):S220–5.CrossRefPubMedPubMedCentral

94.

Gilchrist G, Swan D, Widyaratna K, Marquez-Arrico JE, Hughes E, Mdege ND, et al. A systematic review and meta-analysis of psychosocial interventions to reduce drug and sexual blood borne virus risk behaviours among people who inject drugs. AIDS Behav. 2017;21(7):1791–811.CrossRefPubMedPubMedCentral

95.

Sipe TA, Barham TL, Johnson WD, Joseph HA, Tungol-Ashmon ML, O’Leary A. Structural interventions in HIV prevention: a taxonomy and descriptive systematic review. AIDS Behav. 2017;21(12):3366–430.CrossRefPubMedPubMedCentral

96.

Werb D, Buxton J, Shoveller J, Richardson C, Rowell G, Wood E. Interventions to prevent the initiation of injection drug use: a systematic review. Drug Alcohol Depend. 2013;133(2):669–76.CrossRefPubMed

97.

Centers for Disease Control and Prevention. HIV among women. https://www.cdc.gov/hiv/group/gender/women/index.html. Accessed 9 March 2018.

98.

Centers for Disease Control and Prevention. HIV Surveillance in Women, 2015. https://www.cdc.gov/hiv/library/slideSets/index.html. Accessed 21 Aug 2018.

99.

Reif S, Pence BW, Hall I, Hu X, Whetten K, Wilson E. HIV diagnoses, prevalence and outcomes in Nine Southern States. J Community Health. 2015;40(4):642–51.CrossRefPubMed

100.

Elopre L, Kudroff K, Westfall AO, Overton ET, Mugavero MJ. Brief report: the right people, right places, and right practices: disparities in PrEP access among African American men, women, and MSM in the deep South. J Acquir Immune Defic Syndr. 2017;74(1):56–9.CrossRefPubMedPubMedCentral

101.

Centers for Disease Control and Prevention. HIV Among People Aged 50 and Over. https://www.cdc.gov/hiv/group/age/olderamericans/index.html. Accessed 12 Feb 2018.

102.

Roberson DW. Meeting the HIV prevention needs of older adults. J Assoc Nurses AIDS Care. 2018;29(1):126–9.CrossRefPubMed

103.

Franconi I, Guaraldi G. Pre-exposure prophylaxis for HIV infection in the older patient: what can be recommended? Drugs Aging. 2018. https://doi.org/10.1007/s40266-018-0553-3.CrossRefPubMed

104.

Mitchell JW. The use of technology to advance HIV prevention for couples. Curr HIV/AIDS Rep. 2015;12(4):516–22.CrossRefPubMedPubMedCentral

105.

Sullivan PS, Jones J, Kishore N, Stephenson R. The roles of technology in primary HIV prevention for men who have sex with men. Curr HIV/AIDS Rep. 2015;12(4):481–8.CrossRefPubMed

106.

Anand T, Nitpolprasert C, Trachunthong D, Kerr SJ, Janyam S, Linjongrat D, et al. A novel online-to-offline (O2O) model for pre-exposure prophylaxis and HIV testing scale up. J Int AIDS Soc. 2017;20(1):21326.CrossRefPubMedPubMedCentral

Title: A Review of Approaches Used to Increase Awareness of Pre-exposure Prophylaxis (PrEP) in the United States
Authors: Amber I. Sophus
Jason W. Mitchell
Publication date: 01-07-2019
Publisher: Springer US
Published in: AIDS and Behavior / Issue 7/2019
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-018-2305-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A Review of Approaches Used to Increase Awareness of Pre-exposure Prophylaxis (PrEP) in the United States

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2019

Vulnerable at Each Step in the PMTCT Care Cascade: High Loss to Follow Up During Pregnancy and the Postpartum Period in Tanzania

Health Care Facility Characteristics are Associated with Variation in Human Immunodeficiency Virus Pre-exposure Prophylaxis Initiation in Veteran’s Health Administration

Trends in Attitudes to and the Use of HIV Pre-exposure Prophylaxis by Australian Gay and Bisexual Men, 2011–2017: Implications for Further Implementation from a Diffusion of Innovations Perspective

Applying the Information–Motivation–Behavioral Skills Model to Understand PrEP Intentions and Use Among Men Who Have Sex with Men

Factors Associated with Awareness of Pre-exposure Prophylaxis for HIV Among Persons Who Inject Drugs in Philadelphia: National HIV Behavioral Surveillance, 2015

The Association Between Disclosure of Same Sex Behavior to Healthcare Providers and PrEP Awareness Among BMSM in Baltimore

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page